- Home
- EPAM vs ROIV Comparison
EPAM vs ROIV Comparison
Compare EPAM & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPAM
- ROIV
- Stock Information
- Founded
- EPAM 1993
- ROIV 2014
- Country
- EPAM United States
- ROIV United Kingdom
- Employees
- EPAM N/A
- ROIV N/A
- Industry
- EPAM EDP Services
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- EPAM Technology
- ROIV Health Care
- Exchange
- EPAM Nasdaq
- ROIV Nasdaq
- Market Cap
- EPAM 9.8B
- ROIV 8.6B
- IPO Year
- EPAM 2012
- ROIV N/A
- Fundamental
- Price
- EPAM $156.08
- ROIV $14.08
- Analyst Decision
- EPAM Buy
- ROIV Strong Buy
- Analyst Count
- EPAM 14
- ROIV 4
- Target Price
- EPAM $222.21
- ROIV $15.50
- AVG Volume (30 Days)
- EPAM 826.8K
- ROIV 6.4M
- Earning Date
- EPAM 11-06-2025
- ROIV 11-11-2025
- Dividend Yield
- EPAM N/A
- ROIV N/A
- EPS Growth
- EPAM 0.62
- ROIV N/A
- EPS
- EPAM 7.02
- ROIV N/A
- Revenue
- EPAM $5,071,013,000.00
- ROIV $23,233,000.00
- Revenue This Year
- EPAM $16.65
- ROIV N/A
- Revenue Next Year
- EPAM $7.20
- ROIV $281.14
- P/E Ratio
- EPAM $22.24
- ROIV N/A
- Revenue Growth
- EPAM 9.73
- ROIV N/A
- 52 Week Low
- EPAM $138.15
- ROIV $8.73
- 52 Week High
- EPAM $269.00
- ROIV $14.48
- Technical
- Relative Strength Index (RSI)
- EPAM 39.88
- ROIV 76.40
- Support Level
- EPAM $150.87
- ROIV $11.85
- Resistance Level
- EPAM $173.45
- ROIV $14.48
- Average True Range (ATR)
- EPAM 5.35
- ROIV 0.42
- MACD
- EPAM -1.88
- ROIV 0.21
- Stochastic Oscillator
- EPAM 20.04
- ROIV 86.26
About EPAM EPAM Systems Inc.
EPAM Systems is a global IT services firm that offers platform engineering, software development, and consulting services. EPAM's largest market is North America, which represents approximately 60% of revenue. Offerings span assisting companies with new technologies, such as artificial intelligence, virtual reality, and robotics.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.